HCWB - HCW Biologics Inc. Stock Price, Fair Value and News

1.11USD+0.01 (+0.91%)Delayed

Market Summary

USD1.11+0.01

Delayed

0.91%

HCWB Stock Price

View Fullscreen

HCWB RSI Chart

HCWB Valuation

Market Cap

42.0M

Price/Earnings (Trailing)

-1.53

Price/Sales (Trailing)

10.69

Price/Free Cashflow

-1.47

HCWB Price/Sales (Trailing)

HCWB Profitability

Operating Margin

29.61%

Return on Equity

-313.38%

Return on Assets

-90.02%

Free Cashflow Yield

-67.91%

HCWB Fundamentals

HCWB Revenue

Revenue (TTM)

3.9M

Rev. Growth (Yr)

14.72%

Rev. Growth (Qtr)

-14.9%

HCWB Earnings

Earnings (TTM)

-27.4M

Earnings Growth (Yr)

-47.28%

Earnings Growth (Qtr)

30.08%

Breaking Down HCWB Revenue

Last 7 days

-1.8%

Last 30 days

-30.2%

Last 90 days

-5.1%

Trailing 12 Months

-25.4%

How does HCWB drawdown profile look like?

HCWB Financial Health

Current Ratio

0.46

Debt/Equity

0.95

Debt/Cashflow

-2.72

HCWB Investor Care

Shares Dilution (1Y)

5.39%

Diluted EPS (TTM)

-0.76

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	3.9M	0	0	0
2023	5.8M	4.8M	3.8M	2.8M
2022	0	0	0	6.7M
2021	0	0	0	0
2020	0	0	0	4.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of HCW Biologics Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 20, 2024	greene rick s.	acquired	49,999	1.4	35,714	-
Feb 20, 2024	wong hing c	acquired	1,035,000	1.4	739,288	chief executive officer
Feb 20, 2024	byam rebecca	acquired	1,065,000	1.4	760,714	chief financial officer
Feb 20, 2024	flowers lee	acquired	100,001	1.4	71,429	svp of business development
Feb 20, 2024	giles lisa m.	acquired	50,001	1.4	35,715	-
Feb 20, 2024	garrett scott t	acquired	200,001	1.4	142,858	-
Dec 11, 2023	rhode peter	acquired	1,960	0.14	14,000	see remarks
Dec 08, 2023	flowers lee	acquired	1,050	0.14	7,501	svp of business development
Nov 17, 2023	rhode peter	acquired	2,100	0.14	15,000	see remarks
Oct 19, 2023	byam rebecca	acquired	6,614	0.14	47,249	chief financial officer

Which funds bought or sold HCWB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	new	-	30,182	30,182	-%
May 15, 2024	STATE STREET CORP	unchanged	-	9,544	35,815	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	added	3,590	697	710	-%
May 15, 2024	Cresset Asset Management, LLC	unchanged	-	69,295	230,983	-%
May 15, 2024	AE Wealth Management LLC	unchanged	-	19,500	52,500	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-12.89	1,697	8,642	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	unchanged	-	11,886	39,620	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	37,691	141,449	-%
May 15, 2024	Royal Bank of Canada	reduced	-17.57	-	-	-%
May 15, 2024	CITADEL ADVISORS LLC	sold off	-100	-12,680	-	-%

Are Funds Buying or Selling HCWB?

Are funds buying HCWB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own HCWB

No. of Funds

Recent SEC filings of HCW Biologics Inc.

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-K/A	Annual Report
May 15, 2024	10-Q	Quarterly Report
May 15, 2024	8-K	Current Report
May 03, 2024	8-K	Current Report
May 01, 2024	8-K	Current Report
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 01, 2024	10-K	Annual Report
Apr 01, 2024	8-K	Current Report

Peers (Alternatives to HCW Biologics Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

HCW Biologics Inc. News

Latest updates

HCW Biologics Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q2
Revenue	-14.9%	1,126,712	1,324,002	853,102	622,807	982,164	1,341,520	1,809,025	454,000	3,117,545	-	-	-	-	-	-
Cost Of Revenue	-52.2%	511,965	1,071,357	678,325	502,402	29,350	1,073,216	1,447,220	287,200	1,328,076	-	-	-	-	-	-
Gross Profit	143.3%	614,747	252,645	174,777	120,405	12,533	268,304	361,805	166,800	1,789,469	-	-	-	-	-	-
Operating Expenses	-26.4%	8,108,410	11,020,835	5,252,657	4,630,926	5,373,103	5,935,541	4,381,460	3,677,877	3,670,279	3,112,505	4,092,164	2,750,993	3,412,172	-	2,780,007
S&GA Expenses	-100.0%	-	3,634,439	3,585,215	3,014,260	3,117,290	3,005,529	1,732,666	1,707,995	1,880,601	1,629,197	1,404,823	1,077,830	1,082,360	-	711,224
R&D Expenses	-0.6%	2,123,284	2,136,396	1,667,442	1,616,666	2,255,813	2,930,012	2,648,794	1,969,882	1,789,678	1,483,308	2,687,341	1,673,163	2,329,812	-	2,068,783
EBITDA Margin	-	-	-	-	-	-	-	-	-1.76	-1.01	-10.16	-	-	-	-	-
Interest Expenses	100.0%	-	-1,423	95,514	95,514	93,438	94,476	32,184	-	-	-566,267	-2,540	631	568,176	-	-
EBT Margin	-	-	-	-	-	-	-	-	-1.80	-1.03	-11.31	-	-	-	-	-
Net Income	30.1%	-7,468,061	-10,680,530	-4,938,641	-4,304,420	-5,070,686	-5,418,741	-3,914,194	-3,510,561	-2,057,207	-3,173,406	-4,094,704	-2,750,362	-2,843,996	2,060,805	-2,778,485
Net Income Margin	20.7%	-6.98	-8.80	-5.18	-3.91	-3.11	-2.22	-3.09	-3.13	-2.95	-3.14	-1.86	-1.52	-1.53	-1.42	-
Free Cashflow	50.9%	-3,733,579	-7,610,442	-6,219,320	-10,948,361	-3,938,598	-3,858,058	-12,484,721	-2,702,743	-1,615,716	-3,396,446	-5,123,013	-990,440	-1,513,081	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	6.7%	30.00	29.00	36.00	39.00	44.00	47.00	51.00	47.00	51.00	54.00	56.00	13.00	15.00
Current Assets	-3.1%	6.00	6.00	14.00	20.00	30.00	34.00	29.00	35.00	38.00	40.00	44.00	10.00	12.00
Cash Equivalents	13.4%	4.00	4.00	11.00	7.00	18.00	22.00	26.00	15.00	18.00	12.00	15.00	5.00	8.00
Net PPE	10.5%	23.00	20.00	15.00	13.00	12.00	11.00	11.00	1.00	1.00	1.00	1.00	1.00	2.00
Liabilities	44.1%	22.00	15.00	12.00	11.00	11.00	9.00	9.00	1.00	2.00	2.00	-	-	-
Current Liabilities	53.3%	13.00	9.00	5.00	5.00	5.00	3.00	2.00	1.00	1.00	2.00	2.00	4.00	1.00
Long Term Debt	31.3%	8.00	6.00	6.00	6.00	6.00	6.00	6.00	-	-	-	-	-	-
Shareholder's Equity	-35.1%	9.00	13.00	24.00	29.00	33.00	37.00	43.00	46.00	49.00	51.00	54.00	-	-
Retained Earnings	-10.6%	-78.00	-70.53	-59.85	-54.91	-50.61	-45.54	-40.12	-36.21	-32.69	-30.64	-27.46	-23.24	-16.72
Additional Paid-In Capital	3.3%	87.00	84.00	84.00	83.00	83.00	83.00	83.00	82.00	82.00	82.00	81.00	-	-
Shares Outstanding	5.3%	38.00	36.00	36.00	36.00	36.00	36.00	36.00	36.00	36.00	19.00	30.00	5.00	5.00
Float	-	-	-	-	43.00	-	-	-	44.00	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	7.5%	-3,603	-3,894	-5,589	-9,391	-3,638	-3,789	-2,314	-2,689	-1,592	-3,376	-5,118	-990	-1,489	-	-	-
Share Based Compensation	-6.3%	245	261	220	263	259	286	302	271	260	349	2.00	-	-	-	-	-
Cashflow From Investing	96.5%	-129	-3,715	9,370	-1,556	-300	-68.69	6,814	-12.91	7,976	-23.90	-34,971	-	-23.28	-	-	-
Cashflow From Financing	27788.9%	4,223	-15.25	-8.90	8.00	2.00	-39.85	6,305	6.00	2.00	98,533	-48,361	-814	-86.61	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

HCWB Income Statement

2023-12-31

Statements of Operations - USD ($)	12 Months Ended
Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Revenues:
Revenues	$ 2,841,794	$ 6,722,090
Cost of revenues	(2,281,434)	(4,135,712)
Net revenues	560,360	2,586,378
Operating expenses:
Research and development	7,676,316	9,338,365
General and administrative	13,351,204	8,326,791
Reserve for credit losses	5,250,000	0
Total operating expenses	26,277,520	17,665,156
Loss from operations	(25,717,160)	(15,078,778)
Interest expense	(283,042)	(126,660)
Other (expense) income, net	1,005,925	304,735
Net loss	$ (24,994,277)	$ (14,900,703)
Net loss per share, basic	$ (0.7)	$ (0.42)
Net loss per share, diluted	$ (0.7)	$ (0.42)
Weighted average shares outstanding, basic	35,929,446	35,822,249
Weighted average shares outstanding, diluted	35,929,446	35,822,249

HCWB Balance Sheet

2023-12-31

Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 3,595,101	$ 22,326,356
Short-term investments	0	9,735,930
Accounts receivable, net	1,535,757	417,695
Prepaid expenses	1,042,413	1,394,923
Other current assets	230,916	196,015
Total current assets	6,404,187	34,070,919
Investments	1,599,751	1,599,751
Property, plant and equipment, net	20,453,184	10,804,610
Other assets	56,538	333,875
Total assets	28,513,660	46,809,155
Current liabilities:
Accounts payable	6,167,223	1,226,156
Accrued liabilities and other current liabilities	2,580,402	1,730,325
Total current liabilities	8,747,625	2,956,481
Debt, net	6,304,318	6,409,893
Other liabilities	0	14,275
Total Liabilities	15,051,943	9,380,649
Commitments and contingencies (Note 15)
Stockholders' equity:
Common Stock Value	3,603	3,588
Additional paid-in capital	83,990,437	82,962,964
Accumulated deficit	(70,532,323)	(45,538,046)
Total stockholders' equity	13,461,717	37,428,506
Total liabilities and stockholders' equity	$ 28,513,660	$ 46,809,155

About HCW Biologics Inc.

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

CEO	Dr. Hing C. Wong Ph.D.
WEBSITE	hcwbiologics.com
INDUSTRY	Biotechnology
EMPLOYEES	44

HCW Biologics Inc. Frequently Asked Questions

What is the ticker symbol for HCW Biologics Inc.? What does HCWB stand for in stocks?

HCWB is the stock ticker symbol of HCW Biologics Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of HCW Biologics Inc. (HCWB)?

As of Fri May 17 2024, market cap of HCW Biologics Inc. is 41.98 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HCWB stock?

You can check HCWB's fair value in chart for subscribers.

What is the fair value of HCWB stock?

You can check HCWB's fair value in chart for subscribers. The fair value of HCW Biologics Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of HCW Biologics Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for HCWB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is HCW Biologics Inc. a good stock to buy?

The fair value guage provides a quick view whether HCWB is over valued or under valued. Whether HCW Biologics Inc. is cheap or expensive depends on the assumptions which impact HCW Biologics Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HCWB.

What is HCW Biologics Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, HCWB's PE ratio (Price to Earnings) is -1.53 and Price to Sales (PS) ratio is 10.69. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HCWB PE ratio will change depending on the future growth rate expectations of investors.